Abstract
In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.
Original language | English (US) |
---|---|
Pages (from-to) | 404-406 |
Number of pages | 3 |
Journal | Annals of Neurology |
Volume | 25 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1989 |
All Science Journal Classification (ASJC) codes
- Neurology
- Clinical Neurology